TMAO is both a biomarker and a renal toxin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Systematic review of the effects of the intestinal microbiota on selected nutrients and non-nutrients.European journal of nutrition · 2018
   Pooled it
2. Gut microbiota-derived metabolites in cardiovascular disease: mechanisms, disease-specific roles, and translational opportunities.Frontiers in cardiovascular medicine · 2026
   Review
3. From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge.Frontiers in pharmacology · 2023
   Review
4. Emerging biomarkers for the detection of cardiovascular diseases.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022
   Review
5. Fecal microbiota transplantation restores normal fecal composition and delays malignant development of mild chronic kidney disease in rats.Frontiers in microbiology · 2022
   Article
6. Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease.Nutrients · 2020
   Review
7. Malodorous biogenic amines in Escherichia coli-caused urinary tract infections in women-a metabolomics approach.Scientific reports · 2020
   Article
8. Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota.International journal of biological sciences · 2020
   Article
9. Trimethylamine N-oxide: breathe new life.British journal of pharmacology · 2018
   Review
10. Plasma and urinary metabolomic profiles of Down syndrome correlate with alteration of mitochondrial metabolism.Scientific reports · 2018
    Article
11. Emerging roles of xenobiotic detoxification enzymes in metabolic diseases.Reviews on environmental health · 2017
    Review
12. Dioxin-like pollutants increase hepatic flavin containing monooxygenase (FMO3) expression to promote synthesis of the pro-atherogenic nutrient biomarker trimethylamine N-oxide from dietary precursors.The Journal of nutritional biochemistry · 2016
    Article
13. Effect of a chemical chaperone, tauroursodeoxycholic acid, on HDM-induced allergic airway disease.American journal of physiology. Lung cellular and molecular physiology · 2016
    Article
14. The gut microbiome, diet, and links to cardiometabolic and chronic disorders.Nature reviews. Nephrology · 2016
    Review
15. Trimethylamine N-oxide and kidney diseases: what do we know?Jornal brasileiro de nefrologia
    Review

Corrections and comments

• Comment on
  Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.2015

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as